Updated May 2026 · ClinicalTrials.gov

RECRUITINGPhase 3INTERVENTIONAL

Colchicine After Electrocardioversion for Atrial Fibrillation

Q: What is the NCT05890664 clinical trial studying?

The purpose of this study is to investigate whether a 3 month treatment course of low-dose Colchicine decreases the recurrence of Atrial fibrillation (AF) after electrocardioversion (ECV) in patients with AF. The full protocol is registered on ClinicalTrials.gov and includes the primary outcome measures, eligibility criteria, and study endpoints.

Q: Who can participate in NCT05890664?

Eligibility for this trial depends on the specific inclusion and exclusion criteria set by the sponsor. The plain-English summary above translates the most important criteria into accessible language; the official clinical text is preserved in the collapsible section underneath. Whether you fit any specific trial is a medical decision your doctor needs to confirm — bring the trial information to your treating physician for a full review against your medical history.

Q: How do I contact the trial site for NCT05890664?

Contact information registered with ClinicalTrials.gov is shown in the sidebar of this page. Before reaching out, confirm with your treating physician that this trial is appropriate for your situation. The trial site will then walk you through the screening process to determine final eligibility.

Q: Is participating in a clinical trial safe?

Clinical trials in the United States are regulated by the FDA and overseen by Institutional Review Boards (IRBs) that review the protocol for safety. Risk varies by trial — Phase 1 studies test new treatments in humans for the first time, while Phase 3 trials use treatments that have already passed earlier safety screening. The informed consent document for any specific trial details the known risks and what to expect. Discuss those risks with your physician before deciding whether to participate.

Q: Where can I verify the data on this page?

Every detail on this page comes directly from the ClinicalTrials.gov API. Click "View on ClinicalTrials.gov" in the sidebar to see the official, unmodified record. The federal record is always authoritative; this page is a structured presentation with a plain-English eligibility translation. For background on how clinical trials are regulated, see the FDA drug approval process documentation.

Colchicine After Electrocardioversion for Atrial Fibrillation - The COLECTRO-AF Trial

Colchicine After Electrocardioversion for Atrial Fibrillation (NCT05890664) is a Phase 3 interventional studying Atrial Fibrillation and Cardiac Arrhythmia, sponsored by University Hospital, Basel, Switzerland. RECRUITING as of the most recent ClinicalTrials.gov update. Talk to your doctor before contacting the trial site.

About This Trial

What Stage of Research Is This?

Phase 3 trials confirm efficacy and safety in large patient groups (often 300–3,000+) and form the evidence base for an FDA approval submission. For Atrial Fibrillation, Phase 3 studies typically randomize participants between the investigational treatment and either a placebo or current standard of care. A successful Phase 3 result is the threshold most treatments need to clear before regulatory approval.

This trial is currently recruiting participants. The sponsor has registered the study with ClinicalTrials.gov as actively enrolling, which means new applicants who meet the eligibility criteria can be considered for screening. Trial status can change between updates — confirm current recruiting status with the study contact before traveling for a screening visit.

A target enrollment of 416 participants makes this a sizable late-stage trial. Studies in this range typically have enough power to detect clinically meaningful differences from a comparator and to characterize less-common side effects.

Who May Be Eligible (Plain English)

Who May Qualify: - Age \>18 years - ECG-documented AF prior to ECV - Successful ECV with conversion of AF to sinus rhythm with persistent sinus rhythm ≥30 minutes after ECV - Ability to give written willing to sign a consent form Who Should NOT Join This Trial: - AF persistence after cardioversion or early AF recurrence within 30 minutes after ECV - Any other rhythm than AF before cardioversion - Pulmonary vein isolation within 3 months prior to ECV or pulmonary vein isolation planned within 3 months after ECV - Known intolerance or hypersensitivity to Colchicine - Any other absolute indication for Colchicine intake - Intake of a strong inhibitor of CYP3A4 or P-Glycoprotein (clarithromycin, erythromycin, telithromycin, cyclosporine, ketoconazole or itraconazole) - Serious gastrointestinal disease (severe gastritis or diarrhea) - Clinically overt hepatic disease - Severe renal disease (eGFR\< 30ml/min/1.73m2) - Clinically significant blood dyscrasia (e.g., myelodysplasia) - Significant immunosuppression (e.g. due to transplantation or rheumatic disease) - Pregnant or breastfeeding women, or women of child-bearing potential who do not use a highly effective form of birth control - Life expectancy \<1 year Always talk to your doctor about whether this trial is right for you.

These are translations of the protocol\'s inclusion and exclusion criteria, simplified for patients and caregivers. The original clinical text appears below. Eligibility is ultimately confirmed by the trial site\'s screening process — this summary is a starting point for a conversation with your doctor, not a final determination.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Age \>18 years * ECG-documented AF prior to ECV * Successful ECV with conversion of AF to sinus rhythm with persistent sinus rhythm ≥30 minutes after ECV * Ability to give written informed consent Exclusion Criteria: * AF persistence after cardioversion or early AF recurrence within 30 minutes after ECV * Any other rhythm than AF before cardioversion * Pulmonary vein isolation within 3 months prior to ECV or pulmonary vein isolation planned within 3 months after ECV * Known intolerance or hypersensitivity to Colchicine * Any other absolute indication for Colchicine intake * Intake of a strong inhibitor of CYP3A4 or P-Glycoprotein (clarithromycin, erythromycin, telithromycin, cyclosporine, ketoconazole or itraconazole) * Serious gastrointestinal disease (severe gastritis or diarrhea) * Clinically overt hepatic disease * Severe renal disease (eGFR\< 30ml/min/1.73m2) * Clinically significant blood dyscrasia (e.g., myelodysplasia) * Significant immunosuppression (e.g. due to transplantation or rheumatic disease) * Pregnant or breastfeeding women, or women of child-bearing potential who do not use a highly effective form of birth control * Life expectancy \<1 year

Treatments Being Tested

DRUG

Colchicine

Colchicine 0.5 mg (oral) once daily for 90 days. The chemical name for colchicine is (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol\[a\]heptalen-7-yl) acetamide. Colchicine consists of pale yellow scales or powder. It is soluble in water, freely soluble in alcohol, and slightly soluble in ether.

DRUG

Placebo

Matched placebo. Both the active drug and placebo will look similarly. The route and mode of administration is also similar to the active group.

Locations (8)

Trial sites listed on ClinicalTrials.gov for this study. Site activation status can vary — confirm with the specific site before traveling for a screening visit.

Cantonal Hospital Baselland (KSBL)

Bruderholz, Basel-Landschaft, Switzerland

University Hospital Basel

Basel, Switzerland

University Hospital Bern

Bern, Switzerland

Lausanne University Hospital

Lausanne, Switzerland

Lucerne Cantonal Hospital

Lucerne, Switzerland

Cantonal Hospital Olten

Olten, Switzerland

Herzpraxis am Rhein

Rheinfelden, Switzerland

Solothurner Spitäler AG

Solothurn, Switzerland

How to Talk to Your Doctor About This Trial

Bring the printable summary of this trial — including the NCT ID (NCT05890664), the sponsor (University Hospital, Basel, Switzerland), and the key eligibility criteria — to your next appointment. Your doctor can review the inclusion and exclusion criteria against your medical history, lab values, and current treatments to assess whether you are likely to qualify. They can also help you weigh whether trial participation makes sense alongside your existing care plan.

Useful questions to walk through together: What does the trial protocol require beyond standard care? How long is the active treatment phase, and how long is follow-up? Are there study visits at sites I can reach? Who pays for the trial-specific procedures, and who pays for standard-of-care portions? See our 25 questions to ask about clinical trials guide for a more complete checklist.

Authoritative Sources

The official record for this trial lives on ClinicalTrials.gov — the federal registry maintained by the National Library of Medicine at NIH. For background on how this trial fits into the FDA approval pathway, see the FDA drug approval process. For oncology-specific guidance for patients considering trials, the National Cancer Institute publishes patient-oriented overviews. International trial registries are aggregated by the WHO ICTRP.

Frequently Asked Questions

What is the NCT05890664 clinical trial studying?

The purpose of this study is to investigate whether a 3 month treatment course of low-dose Colchicine decreases the recurrence of Atrial fibrillation (AF) after electrocardioversion (ECV) in patients with AF. The full protocol is registered on ClinicalTrials.gov and includes the primary outcome measures, eligibility criteria, and study endpoints.

Who can participate in NCT05890664?

Eligibility for this trial depends on the specific inclusion and exclusion criteria set by the sponsor. The plain-English summary above translates the most important criteria into accessible language; the official clinical text is preserved in the collapsible section underneath. Whether you fit any specific trial is a medical decision your doctor needs to confirm — bring the trial information to your treating physician for a full review against your medical history.

How do I contact the trial site for NCT05890664?

Contact information registered with ClinicalTrials.gov is shown in the sidebar of this page. Before reaching out, confirm with your treating physician that this trial is appropriate for your situation. The trial site will then walk you through the screening process to determine final eligibility.

Is participating in a clinical trial safe?

Clinical trials in the United States are regulated by the FDA and overseen by Institutional Review Boards (IRBs) that review the protocol for safety. Risk varies by trial — Phase 1 studies test new treatments in humans for the first time, while Phase 3 trials use treatments that have already passed earlier safety screening. The informed consent document for any specific trial details the known risks and what to expect. Discuss those risks with your physician before deciding whether to participate.

Where can I verify the data on this page?

Every detail on this page comes directly from the ClinicalTrials.gov API. Click "View on ClinicalTrials.gov" in the sidebar to see the official, unmodified record. The federal record is always authoritative; this page is a structured presentation with a plain-English eligibility translation. For background on how clinical trials are regulated, see the FDA drug approval process documentation.

How This Page Is Built

Every field on this page is pulled directly from the ClinicalTrials.gov API v2 — no estimates, no proxies. The plain-English eligibility translation is generated from the original protocol text and reviewed for fidelity to the underlying clinical criteria. The original clinical text remains visible in the collapsible section above so users and clinicians can verify the translation. Read the full methodology for the data pipeline and known limitations.

Source: ClinicalTrials.gov API v2 record for NCT05890664. Maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. NCT05890664. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-05-08 · Data from ClinicalTrials.gov.